|
|
|
A BILL TO BE ENTITLED
|
|
AN ACT
|
|
relating to the controlled substances listed in Penalty Groups 1, |
|
2, and 2-A under the Texas Controlled Substances Act. |
|
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: |
|
SECTION 1. Section 481.102, Health and Safety Code, is |
|
amended to read as follows: |
|
Sec. 481.102. PENALTY GROUP 1. Penalty Group 1 consists |
|
of: |
|
(1) the following opiates, including their isomers, |
|
esters, ethers, salts, and salts of isomers, esters, and ethers, |
|
unless specifically excepted, if the existence of these isomers, |
|
esters, ethers, and salts is possible within the specific chemical |
|
designation: |
|
Alfentanil; |
|
Allylprodine; |
|
Alphacetylmethadol; |
|
Benzethidine; |
|
Betaprodine; |
|
Clonitazene; |
|
Diampromide; |
|
Diethylthiambutene; |
|
Difenoxin not listed in Penalty Group 3 or 4; |
|
Dimenoxadol; |
|
Dimethylthiambutene; |
|
Dioxaphetyl butyrate; |
|
Dipipanone; |
|
Ethylmethylthiambutene; |
|
Etonitazene; |
|
Etoxeridine; |
|
Furethidine; |
|
Hydroxypethidine; |
|
Ketobemidone; |
|
Levophenacylmorphan; |
|
Meprodine; |
|
Methadol; |
|
Moramide; |
|
Morpheridine; |
|
Noracymethadol; |
|
Norlevorphanol; |
|
Normethadone; |
|
Norpipanone; |
|
Phenadoxone; |
|
Phenampromide; |
|
Phenomorphan; |
|
Phenoperidine; |
|
Piritramide; |
|
Proheptazine; |
|
Properidine; |
|
Propiram; |
|
Sufentanil; |
|
Tilidine; and |
|
Trimeperidine; |
|
(2) the following opium derivatives, their salts, |
|
isomers, and salts of isomers, unless specifically excepted, if the |
|
existence of these salts, isomers, and salts of isomers is possible |
|
within the specific chemical designation: |
|
Acetorphine; |
|
Acetyldihydrocodeine; |
|
Benzylmorphine; |
|
Codeine methylbromide; |
|
Codeine-N-Oxide; |
|
Cyprenorphine; |
|
Desomorphine; |
|
Dihydromorphine; |
|
Drotebanol; |
|
Etorphine, except hydrochloride salt; |
|
Heroin; |
|
Hydromorphinol; |
|
Methyldesorphine; |
|
Methyldihydromorphine; |
|
Monoacetylmorphine; |
|
Morphine methylbromide; |
|
Morphine methylsulfonate; |
|
Morphine-N-Oxide; |
|
Myrophine; |
|
Nicocodeine; |
|
Nicomorphine; |
|
Normorphine; |
|
Pholcodine; and |
|
Thebacon; |
|
(3) the following substances, however produced, |
|
except those narcotic drugs listed in another group: |
|
(A) Opium and opiate not listed in Penalty Group |
|
3 or 4, and a salt, compound, derivative, or preparation of opium or |
|
opiate, other than thebaine derived butorphanol, nalmefene and its |
|
salts, naloxone and its salts, and naltrexone and its salts, but |
|
including: |
|
Codeine not listed in Penalty Group 3 or 4; |
|
Dihydroetorphine; |
|
Ethylmorphine not listed in Penalty Group 3 |
|
or 4; |
|
Granulated opium; |
|
Hydrocodone not listed in Penalty Group 3; |
|
Hydromorphone; |
|
Metopon; |
|
Morphine not listed in Penalty Group 3; |
|
Opium extracts; |
|
Opium fluid extracts; |
|
Oripavine; |
|
Oxycodone; |
|
Oxymorphone; |
|
Powdered opium; |
|
Raw opium; |
|
Thebaine; and |
|
Tincture of opium; |
|
(B) a salt, compound, isomer, derivative, or |
|
preparation of a substance that is chemically equivalent or |
|
identical to a substance described by Paragraph (A), other than the |
|
isoquinoline alkaloids of opium; |
|
(C) Opium poppy and poppy straw; |
|
(D) Cocaine, including: |
|
(i) its salts, its optical, position, and |
|
geometric isomers, and the salts of those isomers; |
|
(ii) coca leaves and a salt, compound, |
|
derivative, or preparation of coca leaves; and |
|
(iii) a salt, compound, derivative, or |
|
preparation of a salt, compound, or derivative that is chemically |
|
equivalent or identical to a substance described by Subparagraph |
|
(i) or (ii), other than decocainized coca leaves or extractions of |
|
coca leaves that do not contain cocaine or ecgonine; and |
|
(E) concentrate of poppy straw, meaning the crude |
|
extract of poppy straw in liquid, solid, or powder form that |
|
contains the phenanthrine alkaloids of the opium poppy; |
|
(4) the following opiates and opioids, including their |
|
isomers, esters, ethers, salts, and salts of isomers, if the |
|
existence of these isomers, esters, ethers, and salts is possible |
|
within the specific chemical designation: |
|
(A) [Acetyl-alpha-methylfentanyl
|
|
(N-[1-(1-methyl-2- phenethyl)-4-piperidinyl]-N-phenylacetamide);
|
|
[Alpha-methylthiofentanyl (N-[1-methyl-2-(2-
|
|
thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);] |
|
Alphaprodine; |
|
Anileridine; |
|
[Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-
|
|
phenethyl)-4-piperidinyl] -N-phenylpropanamide);
|
|
[Beta-hydroxy-3-methylfentanyl;] |
|
Bezitramide; |
|
[Carfentanil;] |
|
Dihydrocodeine not listed in Penalty Group 3 or 4; |
|
Diphenoxylate not listed in Penalty Group 3 or 4; |
|
Fentanyl [or alpha-methylfentanyl, or any other
|
|
derivative of Fentanyl]; |
|
Isomethadone; |
|
Levomethorphan; |
|
Levorphanol; |
|
Metazocine; |
|
Methadone; |
|
Methadone-Intermediate, 4-cyano-2-dimethylamino- |
|
4, 4-diphenyl butane; |
|
[3-methylfentanyl(N-[3-methyl-1-(2-phenylethyl)-
|
|
4-piperidyl]-N-phenylpropanamide);
|
|
[3-methylthiofentanyl(N-[3-methyl-1-(2-thienyl)
|
|
ethyl-4-piperidinyl]-N-phenylpropanamide);] |
|
Moramide-Intermediate, 2-methyl-3-morpholino-1, |
|
1-diphenyl-propane-carboxylic acid; |
|
Para-fluorofentanyl(N-(4-fluorophenyl)-N-1-(2- |
|
phenylethyl)-4-piperidinylpropanamide); |
|
PEPAP (1-(2-phenethyl)-4-phenyl-4- |
|
acetoxypiperidine); |
|
Pethidine (Meperidine); |
|
Pethidine-Intermediate-A, 4-cyano-1-methyl-4- |
|
phenylpiperidine; |
|
Pethidine-Intermediate-B, ethyl-4- |
|
phenylpiperidine-4 carboxylate; |
|
Pethidine-Intermediate-C, 1-methyl-4- |
|
phenylpiperidine-4-carboxylic acid; |
|
Phenazocine; |
|
Piminodine; |
|
Racemethorphan; and |
|
Racemorphan[;
|
|
[Remifentanil; and
|
|
[Thiofentanyl(N-phenyl-N-[1-(2-thienyl)ethyl-4-
|
|
piperidinyl]-propanamide)]; and |
|
(B) a substance related to fentanyl, unless |
|
specifically excepted or controlled in another Penalty Group, |
|
including any substance that is structurally related to fentanyl by |
|
one or more of the following modifications: |
|
(i) substitution on or replacement of the |
|
phenethyl group, such as: |
|
Alpha methyl fentanyl; |
|
Benzyl fentanyl; and |
|
Thionyl fentanyl (HCl); |
|
(ii) substitution on the piperidine ring, |
|
such as: |
|
Carfentanil; |
|
3-Fluorofentanyl (HCl); and |
|
4-Phenyl fentanyl (HCl); |
|
(iii) substitution on the aniline ring, |
|
such as: |
|
para-Fluorofentanyl; |
|
meta-Fluorofentanyl; and |
|
ortho-Fluorofentanyl; and |
|
(iv) substitution or replacement of the |
|
N-propionyl group, such as: |
|
Acetyl fentanyl (HCL); |
|
Benzodioxole fentanyl; and |
|
Furanyl fentanyl (HCl); |
|
(5) Flunitrazepam (trade or other name: Rohypnol); |
|
(6) Methamphetamine, including its salts, optical |
|
isomers, and salts of optical isomers; |
|
(7) Phenylacetone and methylamine, if possessed |
|
together with intent to manufacture methamphetamine; |
|
(8) Phencyclidine, including its salts; |
|
(9) Gamma hydroxybutyric acid (some trade or other |
|
names: gamma hydroxybutyrate, GHB), including its salts; |
|
(10) Ketamine; |
|
(11) Phenazepam; |
|
(12) U-47700; |
|
(13) AH-7921; |
|
(14) ADB-FUBINACA; |
|
(15) AMB-FUBINACA; and |
|
(16) MDMB-CHMICA. |
|
SECTION 2. Section 481.103(a), Health and Safety Code, is |
|
amended to read as follows: |
|
(a) Penalty Group 2 consists of: |
|
(1) any quantity of the following hallucinogenic |
|
substances, their salts, isomers, and salts of isomers, unless |
|
specifically excepted, if the existence of these salts, isomers, |
|
and salts of isomers is possible within the specific chemical |
|
designation: |
|
5-(2-aminopropyl)benzofuran (5-APB); |
|
6-(2-aminopropyl)benzofuran (6-APB); |
|
5-(2-aminopropyl)-2,3-dihydrobenzofuran |
|
(5-APDB); |
|
6-(2-aminopropyl)-2,3-dihydrobenzofuran |
|
(6-APDB); |
|
5-(2-aminopropyl)indole (5-IT,5-API); |
|
6-(2-aminopropyl)indole (6-IT,6-API); |
|
1-(benzofuran-5-yl)-N-methylpropan-2-amine |
|
(5-MAPB); |
|
1-(benzofuran-6-yl)-N-methylpropan-2-amine |
|
(6-MAPB); |
|
Benzothiophenylcyclohexylpiperidine (BTCP); |
|
8-bromo-alpha-methyl-benzo[1,2-b:4,5-b']difuran- |
|
4-ethanamine (trade or other name: Bromo-DragonFLY); |
|
Desoxypipradrol (2-benzhydrylpiperidine); |
|
2, 5-dimethoxyamphetamine (some trade or other |
|
names: 2, 5-dimethoxy-alpha-methylphenethylamine; 2, 5-DMA); |
|
Diphenylprolinol (diphenyl(pyrrolidin-2-yl) |
|
methanol, D2PM); |
|
Dronabinol (synthetic) in sesame oil and |
|
encapsulated in a soft gelatin capsule in a U.S. Food and Drug |
|
Administration approved drug product (some trade or other names for |
|
Dronabinol: (a6aR-trans)-6a,7,8,10a-tetrahydro- 6,6, 9- |
|
trimethyl-3-pentyl-6H- dibenzo [b,d]pyran-1-ol or (-)-delta-9- |
|
(trans)- tetrahydrocannabinol); |
|
Ethylamine Analog of Phencyclidine (some trade or |
|
other names: N-ethyl-1-phenylcyclohexylamine, (1- |
|
phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexyl) ethylamine, |
|
cyclohexamine, PCE); |
|
2-ethylamino-2-(3-methoxyphenyl)cyclohexanone |
|
(trade or other name: methoxetamine); |
|
Ibogaine (some trade or other names: 7-Ethyl-6, |
|
6, beta 7, 8, 9, 10, 12, 13-octahydro-2-methoxy-6, 9-methano-5H- |
|
pyrido [1', 2':1, 2] azepino [5, 4-b] indole; tabernanthe iboga.); |
|
5-iodo-2-aminoindane (5-IAI); |
|
Mescaline; |
|
5-methoxy-3, 4-methylenedioxy amphetamine; |
|
4-methoxyamphetamine (some trade or other |
|
names: 4-methoxy-alpha-methylphenethylamine; |
|
paramethoxyamphetamine; PMA); |
|
4-methoxymethamphetamine (PMMA); |
|
2-(2-methoxyphenyl)-2-(methylamino)cyclohexanone |
|
(some trade and other names: 2-MeO-ketamine; methoxyketamine); |
|
1-methyl- 4-phenyl-4-propionoxypiperidine (MPPP, |
|
PPMP); |
|
4-methyl-2, 5-dimethoxyamphetamine (some trade |
|
and other names: 4-methyl-2, 5-dimethoxy-alpha- |
|
methylphenethylamine; "DOM"; "STP"); |
|
3,4-methylenedioxy methamphetamine (MDMA, MDM); |
|
3,4-methylenedioxy amphetamine; |
|
3,4-methylenedioxy N-ethylamphetamine (Also |
|
known as N-ethyl MDA); |
|
5,6-methylenedioxy-2-aminoindane (MDAI); |
|
Nabilone (Another name for nabilone: (+)-trans- |
|
3-(1,1-dimethylheptyl)- 6,6a, 7,8,10,10a-hexahydro-1-hydroxy- 6, |
|
6-dimethyl-9H-dibenzo[b,d] pyran-9-one; |
|
N-benzylpiperazine (some trade or other |
|
names: BZP; 1-benzylpiperazine); |
|
N-ethyl-3-piperidyl benzilate; |
|
N-hydroxy-3,4-methylenedioxyamphetamine (Also |
|
known as N-hydroxy MDA); |
|
4-methylaminorex; |
|
N-methyl-3-piperidyl benzilate; |
|
Parahexyl (some trade or other names: 3-Hexyl-1- |
|
hydroxy-7, 8, 9, 10-tetrahydro-6, 6, 9-trimethyl-6H-dibenzo [b, d] |
|
pyran; Synhexyl); |
|
1-Phenylcyclohexylamine; |
|
1-Piperidinocyclohexanecarbonitrile (PCC); |
|
Pyrrolidine Analog of Phencyclidine (some trade |
|
or other names: 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP); |
|
Tetrahydrocannabinols, other than marihuana, and |
|
synthetic equivalents of the substances contained in the plant, or |
|
in the resinous extractives of Cannabis, or synthetic substances, |
|
derivatives, and their isomers with similar chemical structure, |
|
[and pharmacological activity] such as: |
|
delta-9-tetrahydrocannabinolic acid (some |
|
trade name or other name: THCA-A and THCA-B); |
|
delta-9-tetrahydrocannabinol, and its |
|
optical isomers; |
|
delta-1 cis or trans tetrahydrocannabinol, |
|
and their optical isomers; |
|
delta-6 cis or trans tetrahydrocannabinol, |
|
and their optical isomers; |
|
delta-3, 4 cis or trans |
|
tetrahydrocannabinol, and its optical isomers; or |
|
compounds of these structures, regardless of |
|
numerical designation of atomic positions, since nomenclature of |
|
these substances is not internationally standardized; |
|
Thiophene Analog of Phencyclidine (some trade or |
|
other names: 1-[1-(2-thienyl) cyclohexyl] piperidine; 2-Thienyl |
|
Analog of Phencyclidine; TPCP, TCP); |
|
1-pyrrolidine (some trade or other name: TCPy); |
|
1-(3-trifluoromethylphenyl)piperazine (trade or |
|
other name: TFMPP); and |
|
3,4,5-trimethoxy amphetamine; |
|
(2) Phenylacetone (some trade or other |
|
names: Phenyl-2-propanone; P2P, Benzymethyl ketone, methyl benzyl |
|
ketone); |
|
(3) unless specifically excepted or unless listed in |
|
another Penalty Group, a material, compound, mixture, or |
|
preparation that contains any quantity of the following substances |
|
having a potential for abuse associated with a depressant or |
|
stimulant effect on the central nervous system: |
|
Aminorex (some trade or other |
|
names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; 4,5-dihydro-5- |
|
phenyl-2-oxazolamine); |
|
Amphetamine, its salts, optical isomers, and |
|
salts of optical isomers; |
|
Cathinone (some trade or other names: 2-amino-1- |
|
phenyl-1-propanone, alpha-aminopropiophenone, 2- |
|
aminopropiophenone); |
|
Etaqualone and its salts; |
|
Etorphine Hydrochloride; |
|
Fenethylline and its salts; |
|
Lisdexamfetamine, including its salts, isomers, |
|
and salts of isomers; |
|
Mecloqualone and its salts; |
|
Methaqualone and its salts; |
|
Methcathinone (some trade or other names: 2- |
|
methylamino-propiophenone; alpha-(methylamino)propriophenone; |
|
2-(methylamino)-1-phenylpropan-1-one; alpha-N- |
|
methylaminopropriophenone; monomethylpropion; ephedrone, N- |
|
methylcathinone; methylcathinone; AL-464; AL-422; AL-463; and UR |
|
1431); |
|
N-Ethylamphetamine, its salts, optical isomers, |
|
and salts of optical isomers; and |
|
N,N-dimethylamphetamine (some trade or other |
|
names: N,N,alpha-trimethylbenzeneethanamine; |
|
N,N,alpha-trimethylphenethylamine), its salts, optical isomers, |
|
and salts of optical isomers; |
|
(4) any compound structurally derived from |
|
2-aminopropanal by substitution at the 1-position with any |
|
monocyclic or fused-polycyclic ring system, including: |
|
(A) compounds further modified by: |
|
(i) substitution in the ring system to any |
|
extent (including alkyl, alkoxy, alkylenedioxy, haloalkyl, or |
|
halide substituents), whether or not further substituted in the |
|
ring system by other substituents; |
|
(ii) substitution at the 3-position with an |
|
alkyl substituent; or |
|
(iii) substitution at the 2-amino nitrogen |
|
atom with alkyl, benzyl, dialkyl, or methoxybenzyl groups, or |
|
inclusion of the 2-amino nitrogen atom in a cyclic structure; and |
|
(B) by example, compounds such as: |
|
4-Methylmethcathinone (Also known as |
|
Mephedrone); |
|
3,4-Dimethylmethcathinone (Also known as |
|
3,4-DMMC); |
|
3-Fluoromethcathinone (Also known as 3-FMC); |
|
4-Fluoromethcathinone (Also known as |
|
Flephedrone); |
|
3,4-Methylenedioxy-N-methylcathinone (Also |
|
known as Methylone); |
|
3,4-Methylenedioxypyrovalerone (Also known |
|
as MDPV); |
|
alpha-Pyrrolidinopentiophenone (Also known |
|
as alpha-PVP); |
|
Naphthylpyrovalerone (Also known as |
|
Naphyrone); |
|
alpha-Methylamino-valerophenone (Also known |
|
as Pentedrone); |
|
beta-Keto-N-methylbenzodioxolylpropylamine |
|
(Also known as Butylone); |
|
beta-Keto-N-methylbenzodioxolylpentanamine |
|
(Also known as Pentylone); |
|
beta-Keto-Ethylbenzodioxolylbutanamine |
|
(Also known as Eutylone); and |
|
3,4-methylenedioxy-N-ethylcathinone (Also |
|
known as Ethylone); |
|
(5) any compound structurally derived from tryptamine |
|
(3-(2-aminoethyl)indole) or a ring-hydroxy tryptamine: |
|
(A) by modification in any of the following ways: |
|
(i) by substitution at the amine nitrogen |
|
atom of the sidechain to any extent with alkyl or alkenyl groups or |
|
by inclusion of the amine nitrogen atom of the side chain (and no |
|
other atoms of the side chain) in a cyclic structure; |
|
(ii) by substitution at the carbon atom |
|
adjacent to the nitrogen atom of the side chain (alpha-position) |
|
with an alkyl or alkenyl group; |
|
(iii) by substitution in the 6-membered |
|
ring to any extent with alkyl, alkoxy, haloalkyl, thioaklyl, |
|
alkylenedioxy, or halide substituents; or |
|
(iv) by substitution at the 2-position of |
|
the tryptamine ring system with an alkyl substituent; and |
|
(B) including: |
|
(i) ethers and esters of the controlled |
|
substances listed in this subdivision; and |
|
(ii) by example, compounds such as: |
|
alpha-ethyltryptamine; |
|
alpha-methyltryptamine; |
|
Bufotenine (some trade and other names: |
|
3-(beta-Dimethylaminoethyl)-5-hydroxyindole; |
|
3-(2-dimethylaminoethyl)- 5- indolol; N, N-dimethylserotonin; |
|
5-hydroxy-N, N- dimethyltryptamine; mappine); |
|
Diethyltryptamine (some trade and |
|
other names: N, N-Diethyltryptamine, DET); |
|
Dimethyltryptamine (trade or other |
|
name: DMT); |
|
5-methoxy-N, N-diisopropyltryptamine |
|
(5-MeO-DiPT); |
|
O-Acetylpsilocin (Trade or other name: |
|
4-Aco-DMT); |
|
Psilocin; and |
|
Psilocybin; |
|
(6) 2,5-Dimethoxyphenethylamine and any compound |
|
structurally derived from 2,5-Dimethoxyphenethylamine by |
|
substitution at the 4-position of the phenyl ring to any extent |
|
(including alkyl, alkoxy, alkylenedioxy, haloalkyl, or halide |
|
substituents), including, by example, compounds such as: |
|
4-Bromo-2,5-dimethoxyphenethylamine (trade or |
|
other name: 2C-B); |
|
4-Chloro-2,5-dimethoxyphenethylamine (trade or |
|
other name: 2C-C); |
|
2,5-Dimethoxy-4-methylphenethylamine (trade or |
|
other name: 2C-D); |
|
4-Ethyl-2,5-dimethoxyphenethylamine (trade or |
|
other name: 2C-E); |
|
4-Iodo-2,5-dimethoxyphenethylamine (trade or |
|
other name: 2C-I); |
|
2,5-Dimethoxy-4-nitrophenethylamine (trade or |
|
other name: 2C-N); |
|
2,5-Dimethoxy-4-(n)-propylphenethylamine (trade |
|
or other name: 2C-P); |
|
4-Ethylthio-2,5-dimethoxyphenethylamine (trade |
|
or other name: 2C-T-2); |
|
4-Isopropylthio-2,5-dimethoxyphenethylamine |
|
(trade or other name: 2C-T-4); and |
|
2,5-Dimethoxy-4-(n)-propylthiophenethylamine |
|
(trade or other name: 2C-T-7); and |
|
(7) 2,5-Dimethoxyamphetamine and any compound |
|
structurally derived from 2,5-Dimethoxyamphetamine by substitution |
|
at the 4-position of the phenyl ring to any extent (including alkyl, |
|
alkoxy, alkylenedioxy, haloalkyl, or halide substituents), |
|
including, by example, compounds such as: |
|
4-Ethylthio-2,5-dimethoxyamphetamine (trade or |
|
other name: Aleph-2); |
|
4-Isopropylthio-2,5-dimethoxyamphetamine (trade |
|
or other name: Aleph-4); |
|
4-Bromo-2,5-dimethoxyamphetamine (trade or other |
|
name: DOB); |
|
4-Chloro-2,5-dimethoxyamphetamine (trade or |
|
other name: DOC); |
|
2,5-Dimethoxy-4-ethylamphetamine (trade or other |
|
name: DOET); |
|
4-Iodo-2,5-dimethoxyamphetamine (trade or other |
|
name: DOI); |
|
2,5-Dimethoxy-4-methylamphetamine (trade or |
|
other name: DOM); |
|
2,5-Dimethoxy-4-nitroamphetamine (trade or other |
|
name: DON); |
|
4-Isopropyl-2,5-dimethoxyamphetamine (trade or |
|
other name: DOIP); and |
|
2,5-Dimethoxy-4-(n)-propylamphetamine (trade or |
|
other name: DOPR). |
|
SECTION 3. Section 481.1031, Health and Safety Code, is |
|
amended to read as follows: |
|
Sec. 481.1031. PENALTY GROUP 2-A. (a) In this section: |
|
(1) "Core component" is one of the following: |
|
azaindole, beta carboline, benzimidazole, benzothiazole, |
|
carbazole, gamma carboline, imidazole, indane, indazole, indene, |
|
indole, naphthalene, pyrazole, pyrazolopyridine, pyridine, or |
|
pyrrole. |
|
(2) "Group A component" is one of the following: |
|
adamantane, benzylpiperazine, benzyl, cumene [benzene], |
|
cycloalkylmethyl, cyclopropylmethyl, isoquinoline, |
|
methylpiperazine, naphthalene, pyrrolidine, phenyl, quinoline, |
|
tetrahydronaphthalene, tetramethylcyclopropane, amino oxobutane, |
|
amino methyl ovobutane, amino dimethyl oxobutane, amino phenyl |
|
oxopropane, amino oxopentane, ethoxy oxobutane, ethoxy methyl |
|
oxobutane, ethoxy dimethyl oxobutane, ethoxy phenyl oxopropane, |
|
ethoxy oxopentane, methoxy oxobutane, methoxy methyl oxobutane |
|
[methyl methoxy oxobutane], methoxy dimethyl oxobutane, methoxy |
|
phenyl oxopropane, methoxy oxopentane, or any substituted [an] |
|
amino acid. |
|
(3) "Link component" is one of the following |
|
functional groups: carboxamide, carboxylate, hydrazide, |
|
methanone (ketone), ethanone, methanediyl (methylene bridge), or |
|
methine. |
|
(b) Penalty Group 2-A consists of any material, compound, |
|
mixture, or preparation that contains any quantity of a natural or |
|
synthetic chemical substance, including its salts, isomers, and |
|
salts of isomers, listed by name in this subsection or contained |
|
within one of the structural classes defined in this subsection: |
|
(1) WIN-55,212-2; |
|
(2) Cyclohexylphenol: any compound structurally |
|
derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the |
|
5-position of the phenolic ring, (N-methylpiperidin-2-yl)alkyl, |
|
(4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl, whether or |
|
not substituted in the cyclohexyl ring to any extent, including: |
|
JWH-337; |
|
JWH-344; |
|
CP-55,940; |
|
CP-47,497; and |
|
analogues of CP-47,497; |
|
(3) Cannabinol derivatives, except where contained in |
|
marihuana, including tetrahydro derivatives of cannabinol and |
|
3-alkyl homologues of cannabinol or of its tetrahydro derivatives, |
|
such as: |
|
Nabilone; |
|
HU-210; and |
|
HU-211; |
|
(4) Tetramethylcyclopropyl thiazole: any compound |
|
structurally derived from 2,2,3,3-tetramethyl-N-(thiazol- |
|
2-ylidene)cyclopropanecarboxamide by substitution at the nitrogen |
|
atom of the thiazole ring, whether or not further substituted in the |
|
thiazole ring to any extent, whether or not substituted in the |
|
tetramethylcyclopropyl ring to any extent, such as [including]: |
|
A-836,339; |
|
(5) any compound containing a core component |
|
substituted at the 1-position to any extent, and substituted at the |
|
3-position with a link component attached to a group A component, |
|
whether or not the core component or group A component are further |
|
substituted to any extent, such as [including]: |
|
Naphthoylindane; |
|
Naphthoylindazole (THJ-018); |
|
Naphthyl methyl indene (JWH-171); |
|
Naphthoylindole (JWH-018); |
|
Quinolinoyl pyrazole carboxylate (Quinolinyl |
|
fluoropentyl fluorophenyl pyrazole carboxylate); |
|
Naphthoyl pyrazolopyridine; and |
|
Naphthoylpyrrole (JWH-030); |
|
(6) any compound containing a core component |
|
substituted at the 1-position to any extent, and substituted at the |
|
2-position with a link component attached to a group A component, |
|
whether or not the core component or group A component are further |
|
substituted to any extent, such as [including]: |
|
Naphthoylbenzimidazole (JWH-018 Benzimidazole); |
|
and |
|
Naphthoylimidazole; |
|
(7) any compound containing a core component |
|
substituted at the 3-position to any extent, and substituted at the |
|
2-position with a link component attached to a group A component, |
|
whether or not the core component or group A component are further |
|
substituted to any extent, such as [including]: |
|
Naphthoyl benzothiazole; [and] |
|
(8) any compound containing a core component |
|
substituted at the 9-position to any extent, and substituted at the |
|
3-position with a link component attached to a group A component, |
|
whether or not the core component or group A component are further |
|
substituted to any extent, including: |
|
Naphthoylcarbazole (EG-018); and |
|
Synthetic chemical compounds with a carbazole |
|
core structure, regardless of numerical designation of atomic |
|
positions, since this core structure is symmetrical; |
|
(9) any compound containing a core component |
|
substituted at the 1-position to any extent and substituted at the |
|
5-position with a link component attached to a group A component, |
|
regardless of whether the core component or group A component are |
|
further substituted to any extent, such as: |
|
5-fluoro-3,5-ADB-PFUPPYCA (5f-AB-PFUPPYCA); |
|
(10) any compound containing a core component |
|
substituted at the 2-position to any extent and substituted at the |
|
3-position with a link component attached to a group A component, |
|
regardless of whether the core component or group A component are |
|
further substituted to any extent, such as: |
|
AB-CHMINACA (2H) indazole; and |
|
(11) any compound containing a core component |
|
substituted at the 5-position to any extent and substituted at the |
|
2-position with a group A component, regardless of whether the core |
|
component or group A component are further substituted to any |
|
extent, such as: |
|
Cumyl-PeGACLONE. |
|
(c) In this section, a synthetic chemical substance |
|
analogue is: |
|
(1) any substance, unless specifically excepted, that |
|
has two of the three components as defined by Subsection (a) and a |
|
numerical core-link position that is listed in Subsection (b)(5), |
|
(6), (7), (8), (9), or (10); |
|
(2) any substance, unless specifically excepted, that |
|
has a core, link, and group A component as defined by Subsection (a) |
|
but does not have a numerical core-link position that is listed in |
|
Subsection (b)(5), (6), (7), (8), (9), or (10); or |
|
(3) any substance, unless specifically excepted, that |
|
has a core component or group A component as defined by Subsection |
|
(a) and a numerical core-group A position that is listed in |
|
Subsection (b)(11). |
|
SECTION 4. The change in law made by this Act applies only |
|
to an offense committed on or after the effective date of this Act. |
|
An offense committed before the effective date of this Act is |
|
governed by the law in effect on the date the offense was committed, |
|
and the former law is continued in effect for that purpose. For |
|
purposes of this section, an offense was committed before the |
|
effective date of this Act if any element of the offense occurred |
|
before that date. |
|
SECTION 5. This Act takes effect September 1, 2019. |